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Background
Anemia, which is common in the critically ill, is often 
treated with red-cell transfusions which are associated 
with poor clinical outcomes. We hypothesized that therapy 
with recombinant human erythropoietin (epoetin alfa) 
might reduce the need for red-cell transfusions.
Methods
Objective: Evaluate the eﬃ  cacy of epoetin alfa in reducing 
the packed red blood cell transfusion requirement in 
critically ill patients.
Design: Prospective, randomized, double blind, placebo 
controlled, multi-center trial
Setting: 115 medical centers throughout the United States.
Subjects: 1460 patients that had been admitted to 
medical, surgical, or trauma intensive care units. Inclu-
sion criteria included age 18 years or greater, patients 
remained in the ICU for two days, and hemoglobin level 
less than 12 gm/dl. Statistical analysis was performed for 
the entire group, as well as subgroup analysis according 
to the type of ICU to which the patient was admitted (the 
subgroup analysis was included in the initial study 
design).
Intervention: After enrollment, patients randomized to 
the study group received epoetin alfa 40,000 units SQ on 
study day 1, 8, and 15. Th e drug was withheld if the 
hemoglobin level was greater than 12 gm/dl at the time 
of scheduled administration. Patients randomized to the 
placebo group received a placebo injection according to 
the same schedule. All patients enrolled received supple-
mental iron. Patients were given packed red blood cell 
transfusions at the discretion of the treating physician. 
Th e investigators recommended goal hemo globin 
concentration of 7 to 9 gm/dl, and not to transfuse for a 
hemoglobin concentration of greater than 9 gm/dl unless 
a speciﬁ c indication was present.
Outcomes: Th e primary endpoint was percentage of 
patients requiring blood transfusion. Secondary end-
points included number of units transfused, mortality, 
and the change in hemoglobin concentration from baseline.
Results
As compared with the use of placebo, epoetin alfa 
therapy did not result in a decrease in either the number 
of patients who received a red-cell transfusion (relative 
risk for the epoetin alfa group vs. the placebo group, 0.95; 
95% conﬁ dence interval [CI], 0.85 to 1.06) or the mean 
(±SD) number of red-cell units transfused (4.5±4.6 units 
in the epoetin alfa group and 4.3±4.8 units in the placebo 
group, P = 0.42). However, the hemoglobin concentration 
at day 29 increased more in the epoetin alfa group than in 
the placebo group (1.6±2.0 g per deciliter vs. 1.2±1.8 g 
per deciliter, P<0.001). Mortality tended to be lower at 
day 29 among patients receiving epoetin alfa (adjusted 
hazard ratio, 0.79; 95% CI, 0.56 to 1.10); this eﬀ ect was 
also seen in pre-speciﬁ ed analyses in those with a 
diagnosis of trauma (adjusted hazard ratio, 0.37; 95% CI, 
0.19 to 0.72). A similar pattern was seen at day 140 
(adjusted hazard ratio, 0.86; 95% CI, 0.65 to 1.13), 
particularly in those with trauma (adjusted hazard ratio, 
0.40; 95% CI, 0.23 to 0.69). As compared with placebo, 
epoetin alfa was associated with a signiﬁ cant increase in 
the incidence of thrombotic events (hazard ratio, 1.41; 
95% CI, 1.06 to 1.86).
Conclusions
Th e use of epoetin alfa does not reduce the incidence of 
red-cell transfusion among critically ill patients, but it 
may reduce mortality in patients with trauma. Treatment 
with epoetin alfa is associated with an increase in the © 2010 BioMed Central Ltd
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incidence of thrombotic events. (ClinicalTrials.gov 
number, NCT00091910.)
Commentary
Anemia is a common problem in critically ill patients, 
frequently requiring packed red blood cell transfusion. 
Transfusions are associated with potential complications 
(hemolytic transfusion reactions, non-hemolytic transfu-
sion reactions, infectious disease transmissions). Previous 
studies investigated the administration of human 
recombinant erythropoietin to critically ill patients to 
reduce transfusion requirements. Th e ﬁ rst of these 
studies demonstrated fewer transfusions with the 
administration of erythropoietin, though there was no 
diﬀ erence in mortality.1 A similar, larger study was 
performed by many of the same researchers ﬁ nding a 
similar decrease in transfusion requirements in the 
treatment group and no overall mortality diﬀ erence.2 
Additionally, in a post hoc subgroup analysis, they 
identiﬁ ed a mortality beneﬁ t in trauma patients.
Th e current article was performed in order to 
investigate additional outcomes, primarily the safety of 
epoetin alfa for this indication. Th e study design was 
virtually the same as the 2002 study, although the current 
study evaluates mortality beneﬁ t at 140 days (an extended 
time period from conventional 28-day mortality), and 
predetermined subgroup analysis of medical, surgical, 
and trauma ICU patients. It is interesting that the 
ﬁ ndings of this study do not reﬂ ect the transfusion 
beneﬁ t previously demonstrated.
Th e current trial shows no diﬀ erence in the PRBC 
transfusion requirements, no clinically signiﬁ cant diﬀ er-
ence in hemoglobin concentration (though there is a 
statistical diﬀ erence), and no mortality beneﬁ t. So, what 
is the signiﬁ cance of this study? Th e importance of this 
study lies within the predetermined subgroup analysis. In 
these analyses, mortality beneﬁ t was observed in the 
trauma patients, both at 29 days (hazard ratio [HR]=0.37, 
CI:0.19 – 0.72) and at 140 days (HR=0.40, CI: 0.23 – 
0.69). Th e mortality beneﬁ t found in this data is not new. 
Similar ﬁ ndings were shown in the previous trial, where a 
post hoc subgroup analysis was performed in trauma 
patients and mortality beneﬁ t was observed at 29 days 
(HR=0.43, CI: 0.23 – 0.81). Th us, two large studies have 
now shown a mortality beneﬁ t. However, the causal 
mechanisms are unclear. Th e beneﬁ t does not correspond 
to improvement in hemoglobin concentration or 
reduction in transfusion requirement. Th e authors 
speculate that it may be related to non-erythrogenic 
properties of epoetin alfa, such as anti-apoptotic 
characteristics or protection against hypoxemia.
Th e safety evaluation in this trial showed that epoetin 
alfa increases the incidence of clinically relevant throm-
botic events (16.5 vs. 11.5, p = 0.008). Th ese ﬁ ndings, 
however, are not entirely conclusive. With further analysis, 
the authors showed that the increase in throm botic events 
only aﬀ ected patients not receiving heparin prophylaxis. 
Th e incidence of thrombotic events was 20.3 vs. 12.8 
(p=0.008) in patients not receiving prophylaxis, and 12.3 
vs. 10.2 (p=0.41) in patients receiving prophylaxis.
As with previous trials, this is a large, multi-center, 
prospective, blinded, placebo-controlled trial. Why then 
is the transfusion requirement beneﬁ t not reproduced in 
this study? Th is diﬀ erence is likely related to a change in 
transfusion culture. In 1999, the TRICC trial was 
published, and this study showed that a restrictive 
transfusion approach had similar outcomes compared to 
liberal transfusion strategy.3 Previous trials recruited 
patients prior to these ﬁ ndings, whereas the current 
study recruited patients after dissemination of ﬁ ndings of 
the TRICC study. Th e lack of diﬀ erences in transfusion 
requirement in this study may have occurred due to less 
aggressive transfusion practices.
With the current ﬁ ndings, it is evident that epoetin alfa 
administered to critically ill patients does not improve 
transfusion requirements as previously demonstrated. 
Th e mortality beneﬁ t shown in trauma patients should be 
considered, as this beneﬁ t has been found independent of 
transfusion requirement and hemoglobin concentrations 
in two well designed trials. Mechanisms underlying this 
beneﬁ cial eﬀ ect should be examined in future studies. It 
is likely that epoetin alfa can be administered safely to 
critically ill patients that are also receiving heparin in 
prophylactic doses.
Recommendations
Epoetin alfa should not be used in critically ill patients to 
decrease PRBC requirements. Epoetin alfa can be 
considered in critically ill trauma patients as there is a 
demonstrated mortality beneﬁ t, but these patients should 
be able to safely receive prophylactic heparin.
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